Skip to main content
. 2013 Apr 4;24(7):1841–1847. doi: 10.1093/annonc/mdt121

Table 3.

Patients with treatment-related, grade 2 or higher, adverse events that occurred in ≥10% of patients

Adverse event Grade 1
Grade 2
Grade 3
Grade 4
Total
n Percent n Percent n Percent n Percent n Percent
Fatigue 17 44 13 33 2 5 0 0 32 82
Neuropathy, sensorya 10 26 15 38 7 18 0 0 32 82
Anemia 22 56 7 18 0 0 0 0 29 74
Leukopenia 16 41 6 15 3 8 1 3 26 67
Alopecia 10 26 14 36 0 0 0 0 24 62
Hyperglycemia 22 56 1 3 0 0 0 0 23 59
Nausea 16 41 4 10 1 3 0 0 21 54
Myalgias 12 31 7 18 1 3 0 0 20 51
AST 13 33 2 5 2 5 0 0 17 44
Diarrhea 15 38 2 5 0 0 0 0 17 44
Anorexia 10 26 6 15 0 0 0 0 16 41
Arthralgia 6 15 9 23 1 3 0 0 16 41
Neutropenia 6 15 2 5 6 15 1 3 15 38
Alkaline phosphatase 8 21 2 5 3 8 0 0 13 33
Extremity Pain 9 23 4 10 0 0 0 0 13 33
ALT 9 23 3 8 0 0 0 0 12 31
Back pain 7 18 2 5 0 0 1 3 10 26
Constipation 9 23 1 3 0 0 0 0 10 26
Hyponatremia 8 21 0 0 2 5 0 0 10 26
Fever without Neutropenia 9 23 0 0 0 0 0 0 9 23
Headache 7 18 1 3 1 3 1 3 10 26
Stomatitis 7 18 1 3 1 3 0 0 9 23
Rash 5 13 3 8 1 3 0 0 9 23
Vomiting 5 13 4 10 0 0 0 0 9 23
Cough 6 15 2 5 0 0 0 0 8 21
Dyspnea 4 10 3 8 0 0 1 3 8 21
Lymphopenia 8 21 0 0 0 0 0 0 8 21
Thrombocytopenia 8 21 0 0 0 0 0 0 8 21
Allergic reaction 4 10 3 8 0 0 0 0 7 18
Hematologic-other 5 13 0 0 0 0 1 3 6 15
Insomnia 5 13 1 3 0 0 0 0 6 15
Abdominal pain 3 8 2 5 2 5 0 0 7 18
Bone pain 3 8 1 3 1 3 0 0 5 13
Dizziness 4 10 1 3 0 0 0 0 5 13
Hypoalbuminemia 5 13 0 0 0 0 0 0 5 13
Hypoalbuminemia 5 13 0 0 0 0 0 0 5 13
Hypocalcemia 4 10 1 3 0 0 0 0 5 13
Nail changes 2 5 3 8 0 0 0 0 5 13
Dyspepsia 3 8 1 3 0 0 0 0 4 10
Limb edema 4 10 0 0 0 0 0 0 4 10
Influenza-like symptoms 2 5 2 5 0 0 0 0 4 10
Hot flashes 3 8 1 3 0 0 0 0 4 10
Hypernatremia 4 10 0 0 0 0 0 0 4 10
Hypokalemia 3 8 0 0 1 3 0 0 4 10
Rigors/chills 4 10 0 0 0 0 0 0 4 10
Weight loss 3 8 1 3 0 0 0 0 4 10

aSensory neuropathy was assessed and graded according to symptoms as reported by the patient; neurosensory studies were not carried out.